macimorelin

Also Known As:

AEZS-130; ARD-07; Aib-DTrp-DgTrp-CHO; Aib-Trp-gTrp-CHO; EP 1572; EP-1572; EP1572; JMV 1843; JMV-1843; JMV1843; Macrilen; aminoisobutyryl-tryptophyl-tryptophanamine-formyl; macimorelin acetate

Networked: 10 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - macimorelin: 10
Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Essential Amino Acids: 1152
    - Tryptophan: 6733
      - macimorelin: 10
  - Cyclic Amino Acids: 3
    - Aromatic Amino Acids: 467
      - Tryptophan: 6733
        macimorelin: 10

Experts

1.	Ammer, Nicola: 2 articles (08/2021 - 01/2021)
2.	Yuen, Kevin C J: 2 articles (08/2021 - 01/2021)
3.	Buckinx, An: 2 articles (01/2021 - 05/2019)
4.	De Bundel, Dimitri: 2 articles (01/2021 - 05/2019)
5.	Kooijman, Ron: 2 articles (01/2021 - 05/2019)
6.	Pierre, Anouk: 2 articles (01/2021 - 05/2019)
7.	Smolders, Ilse: 2 articles (01/2021 - 05/2019)
8.	Van Den Herrewegen, Yana: 2 articles (01/2021 - 05/2019)
9.	Fehrentz, J A: 2 articles (01/2013 - 11/2011)
10.	Holubová, M: 2 articles (01/2013 - 11/2011)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2013 - "In the present study, we investigated the acute and long term effects of the GHS R1a agonist JMV 1843 (H Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. " 05/01/2009 - "Sixteen healthy subjects (8 males, 8 females) receive ARD-07 on 2 different days; the treatment consists of a single oral dose of ARD-07 (0.5 mg/kg body weight), once with and the second day without a test meal. " 01/01/2023 - "In macimorelin recipients, change in FACIT-F was directly associated with change in body weight (r = 0.92, P = 0.001), IGF-1 (r = 0.80, P = 0.01), and caloric intake (r = 0.83, P = 0.005), and inversely associated with change in energy expenditure (r = -0.67, P = 0.05). " 01/01/2021 - "While macimorelin did not significantly affect food intake or body weight over a 2-week treatment period, its acute orexigenic effect was preserved in epileptic mice but not in sham mice. " 01/01/2023 - "Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. "
2.	Cachexia 01/01/2013 - "Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia." 01/01/2023 - "Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed non-parametrically. " 01/01/2023 - "Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia." 01/01/2023 - "Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. "
3.	Neoplasms (Cancer) 01/01/2023 - "Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed non-parametrically. " 01/01/2023 - "Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia." 01/01/2023 - "Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. "
4.	Epilepsy (Aura) 01/01/2021 - "These findings highlight the potential use of macimorelin as a novel treatment option for seizure suppression in pharmacoresistant epilepsy." 01/01/2021 - "Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy."
5.	Temporal Lobe Epilepsy 01/01/2021 - "While the full ghrelin-R agonist macimorelin was not significantly antiepileptogenic nor disease-modifying, this is the first study to demonstrate its anticonvulsant effects in the IHKA model of drug-refractory temporal lobe epilepsy. "

Related Drugs and Biologics

1.	Ghrelin
2.	Anticonvulsants (Antiepileptic Drugs)
3.	Acids
4.	growth hormone releasing hexapeptide
5.	Ghrelin Receptors
6.	Messenger RNA (mRNA)
7.	Pilocarpine (Ocusert)
8.	Peptides (Polypeptides)
9.	Neuropeptides
10.	Neuropeptide Y

Related Therapies and Procedures

1.	Therapeutics